Roche (RHHBY) Stock Price, News & Analysis

Company Overview

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies. The diagnostics business supplies a broad range of in vitro and molecular diagnostics, tissue‑based pathology solutions, point‑of‑care testing and diabetes care products, along with instruments and assay systems used by hospitals, laboratories and clinics to support clinical decision‑making and patient monitoring.

Roche has a global footprint with operations and research facilities across Europe, the Americas and Asia, and a portfolio that combines internally developed products with offerings from affiliated biotech subsidiaries. The company emphasizes research and development and partnerships to advance precision medicine, leveraging its diagnostics expertise to support the selection and monitoring of appropriate therapies.

Key Stats

• Today's Range: $50.06 to $51.38
• 50-Day Range: $47.39 to $53.34
• 52-Week Range: $37.51 to $60.85
• Volume: 3.41 million shs
• Average Volume: 2.56 million shs
• Market Capitalization: $319.93 billion
• P/E Ratio: N/A
• Dividend Yield: 1.93%
• Price Target: $51.50
• Consensus Rating: Hold

Roche Stock Analysis - MarketRank™

Roche scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Hold

Consensus Rating

Roche has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Roche is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Roche has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 6.36%

Earnings Growth

Earnings for Roche are expected to grow by 6.36% in the coming year, from $3.30 to $3.51 per share.

Price to Earnings Growth Ratio

Roche has a PEG Ratio of 4.31. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Roche has a P/B Ratio of 6.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of Roche has been sold short.

Short Interest Ratio / Days to Cover

Roche has a short interest ratio ("days to cover") of 1.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Roche has recently decreased by 20.40%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Roche pays a meaningful dividend of 1.86%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Roche does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Roche will have a dividend payout ratio of 27.64% next year. This indicates that Roche will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.87

News Sentiment

Roche has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Roche this week, compared to 7 articles on an average week.

MarketBeat Follows

8 people have added Roche to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Roche insiders have not sold or bought any company stock.

Percentage Held by Institutions

Roche has minimal institutional ownership at this time.

Company Calendar

• Today: 6/01/2026
• Next Earnings (Estimated): 7/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:RHHBY
• CIK: N/A
• Web: www.roche.com
• Phone: (161) 688-1111
• Fax: 41-0-61-691-9391
• Employees: 103,249
• Year Founded: 1896

Price Target and Rating

• Average Price Target for Roche: $51.50
• High Price Target: $57.00
• Low Price Target: $46.00
• Potential Upside/Downside: +2.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.45
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 15.22
• P/E Growth: 4.31
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.72
• Current Ratio: 1.38
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: $76.45 billion
• Price / Sales: 4.18
• Cash Flow: $3.45 per share
• Price / Cash Flow: 14.55
• Book Value: $7.18 per share
• Price / Book: 6.99

Miscellaneous

• Outstanding Shares: 6,370,540,000
• Free Float: N/A
• Market Cap: $319.93 billion
• Optionable: Not Optionable
• Beta: 0.50